Archive · 10 Dec 2025
Servier Expands India Focus with Oncology Launches and Trials
Servier, a French drug company, is focusing more on India.
They are launching new medicines for rare cancers, like a drug called Voranigo for brain cancer.
This drug got approved in India just a year after the US, which is much faster than usual.
Servier is also planning to make some of their medicines in India and do important tests there.
They want India to be as important as other big markets.
The company is known for heart and diabetes medicines but has been working on cancer treatments for about 10 years.
They think India will become a bigger part of their business.
Servier is expanding its oncology portfolio in India with new drug launches focused on rare cancers.
The company recently received approval for Voranigo, a treatment for specific types of brain cancer, in India.
Servier plans to conduct global clinical trials in India for the first time, ensuring efficacy and safety in the local setting.
The company is exploring partnerships with domestic contract manufacturers for local production of active pharmaceutical ingredients (APIs).
Servier aims to align its India launches with those in Western markets, significantly elevating India's importance in its global strategy.
- Who
- Servier, a French pharmaceutical company
- What
- Expanding its oncology portfolio and manufacturing presence in India
- When
- Recent approvals and future plans for clinical trials
- Where
- India
- Why
- To grow its market share and align with global launches
- Company
- Servier
- Focus Areas
- Oncology, Rare Cancers
- Recent Approval
- Vorasidenib (Voranigo) for brain cancer
- Revenue (2024)
- €5.9 billion
- India Strategy
- Local manufacturing, global clinical trials
- Other Launches
- Onivyde, Tibsovo
- Governance
- Fondation Internationale de Recherche Servier (FIRS)